{"filing":{"accession_number":"0001000694-26-000019","cik":"0001000694","ticker":"NVAX","company_name":"NOVAVAX INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"nvax-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/nvax-20260806.htm"},"events":[{"id":25367,"run_id":23017,"accession_number":"0001000694-26-000019","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Novavax's second quarter 2026 financial results. The Item 2.02 filing explicitly states \"On August 6, 2026, Novavax, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The disclosure includes detailed quarterly revenue ($57 million), operating expenses, net loss ($53 million), cash position, and updated full-year 2026 financial guidance—all hallmarks of a quarterly earnings announcement material to investors.","company_name":"NOVAVAX INC","ticker":"NVAX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26169,"accession_number":"0001000694-26-000019","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Novavax's second quarter 2026 financial results. The Item 2.02 filing explicitly states \"On August 6, 2026, Novavax, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The disclosure includes detailed quarterly revenue ($57 million), operating expenses, net loss ($53 million), cash position, and updated full-year 2026 financial guidance—all hallmarks of a quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:33.804499+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26169,"accession_number":"0001000694-26-000019","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Novavax's second quarter 2026 financial results. The Item 2.02 filing explicitly states \"On August 6, 2026, Novavax, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The disclosure includes detailed quarterly revenue ($57 million), operating expenses, net loss ($53 million), cash position, and updated full-year 2026 financial guidance—all hallmarks of a quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:35:33.804499+00:00","company_name":"NOVAVAX INC","ticker":"NVAX","filing_date":"2026-08-06"}]}